The abstract is read at the publisher; the summary is JClub's.
Routine typhoid conjugate vaccine at 9 months with catch-up to 15 years and a booster at 5 years is predicted to reduce typhoid cases by a median of 40%-68% over 10 years.
- Why it matters: Waning immunity from TCV creates uncertainty about which dosing schedule best balances health gains and costs across different typhoid incidence settings.
- What they did: Two agent-based and two compartmental dynamic models were fitted to harmonized age-specific incidence data from medium, high, and very high settings, then compared under slow- and fast-waning assumptions using net-monetary-benefit cost-effectiveness with WTP thresholds.
- The result: Across all four models, TCV introduction with catch-up was cost-effective above $1,250 per DALY averted in medium settings when illness costs and CFR are high and in high settings when costs and CFR are low, while fast waning favored delaying routine vaccination to 2 or 5 years and very high settings supported cost-saving at 9 months or 2 years.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.